AUTHOR=Cheng Wei , Ma Xu-Dong , Su Long-Xiang , Long Yun , Liu Da-Wei , Du Bin , Qiu Hai-Bo , Guan Xiang-Dong , Chen De-Chang , Kang Yan , Tong Zhao-Hui , Peng Zhi-Yong , Shang You , Zheng Rui-Qiang , Li Shu-Sheng , Pan Chun , Huang Xiao-Bo , Zhan Qing-Yuan , Ding Ren-Yu , Huang Chao-Lin , Yin Yong-Jie , Li Sheng-Qing , Li Xu-Yan , Jiang Li , Hu Ming , Li Xin , Zhou Xiang , Jing Zhi-Cheng , Guo Yan-Hong , Zhang Shu-Yang 

TITLE=Retrospective Study of Critically Ill COVID-19 Patients With and Without Extracorporeal Membrane Oxygenation Support in Wuhan, China

JOURNAL=Frontiers in Medicine

VOLUME=Volume 8 - 2021

YEAR=2021

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.659793

DOI=10.3389/fmed.2021.659793

ISSN=2296-858X

ABSTRACT=Background: Extracorporeal membrane oxygenation (ECMO) might be benefit for the critically ill COVID-19 patients. But what are the considerations besides indications guiding ECMO initiation under extreme pressure during the COVID-19 epidemic was not clear. We aimed to analyze the clinical characteristics and in-hospital mortality of severe critically ill COVID-19 patients supported with ECMO and without ECMO, exploring potential parameters for guiding the initiation during the COVID-19 epidemic.
Methods: observational cohort study of all the critically ill patients indicated for ECMO support from January 1st to May 1st 2020 in all the 62 authorized hospitals in Wuhan, China.
Results Among the 168 patients enrolled, 74 patients actually received ECMO support and 94 not were analyzed. The in-hospital mortality of the ECMO supported patients was significantly lower than non-ECMO ones（71.6% vs 85.1%, P=0.033）, but the role of ECMO was affected by patients’ age (Logistic regression OR 0.62, P=0.24). As for the ECMO patients, the median age was 58 (47-66) years old and 62.2% (46/74) was male. The 28-day, 60-day and 90-day mortality of these ECMO supported patients were 32.4%, 68.9% and 74.3% respectively. Patients survived to discharge were younger (49 vs 62 years, P=0.042), demonstrated higher lymphocyte count (886 vs 638 cells/uL, P=0.022) and better CO2 removal (PaCO2 immediately after ECMO initiation 39.7 vs 46.9mmHg, P=0.041). Age was an independent risk factor for in-hospital mortality of the ECMO supported patients, and a cutoff age of 51 years enabled prediction of in-hospital mortality with a sensitivity of 84.3% and specificity of 55%. The surviving ECMO supported patients had longer ICU and hospital stay (26 vs 18 days, P=0.018; 49 vs 29 days, P=0.001 respectively), and ECMO procedure was widely carried out after the supplement of medical resources after Feb 15th (67.6%, 50/74).
Conclusions ECMO might be benefit for severe critically ill COVID-19 patients at the early stage of epidemic, although the in-hospital mortality was still high. To initiate ECMO therapy under tremendous pressure, patients’ age, lymphocyte count and adequacy of medical resources should be fully considered.